The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the signing of a memorandum of understanding (MOU) bolstering its ongoing collaboration with the U.S. Food and Drug Administration (FDA). This MOU provides a framework that will enable and encourage the sharing of knowledge and support the formation of research teams to solve complex problems in the area of each agency’s mission, with a focus on the molecular characterization/classification of tumors.

Genetic heterogeneity amongst leukemic cells is a major contributor to low survival rates and poor clinical outcomes for patients with acute myeloid leukemia (AML). This diversity drives complex signaling pathways at the protein level which necessitate individualized treatment protocols for each patient. In order to improve patient outcomes, ex vivo drug sensitivity assays to predict patient-specific drug responses are being researched.

CPTAC investigators from Baylor College of Medicine and the Broad Institute of MIT and Harvard in collaboration with oncologists at Washington University in St. Louis have identified biological markers in triple negative breast cancer (TNBC) that are associated with resistance to chemotherapy treatment.

The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the renewal of partnerships with Australia, Canada, and Germany. These partnerships, through memoranda of understanding (MOUs) to the NCI Cancer Moonshot International Cancer Proteogenome Consortium (ICPC), affirms a commitment to accelerate our understanding of how proteins and genes (proteogenomics) contribute to an individual’s cancer and better inform patient care.

CPTAC investigators from Washington University School of Medicine in St. Louis have developed new multiplexed assays for analyzing kinase proteins by parallel reaction monitoring mass spectrometry (PRM), a targeted form of mass spectrometry that enables highly sensitive and specific measurements. The set of new 408 assays corresponding to 234 unique proteins, present a new community resource for quantifying the proteins and phosphoproteins involved in kinase signaling.

This year, the 8th Annual FedHealthIT Innovation Awards recognized programs from the Department of Veterans Affairs, Military Health, Health and Human Services, and Centers for Medicare and Medicaid Services. These programs were carefully selected by their peers for their commitment to excellence, constant innovation, and producing results.

In May, a leading provider of precision medicine laboratory services, CellCarta, acquired the commercial rights to the CPTAC-qualified antibody panels and assays developed by the Paulovich laboratory at Fred Hutchinson Cancer Center; they produce high-end multiplex quantitative immuno-MRM mass spectrophotometry-based assays for pharmaceutical and biotech industry partners.

This month, the Office of Cancer Clinical Proteomics Research (OCCPR) at the National Cancer Institute (NCI), part of the National Institutes of Health, has reaffirmed its commitment to furthering proteogenomics research by announcing the next round of Proteome Characterization Center (PCC; RFA-CA-21-023), Proteogenomic Data Analysis Center (PGDAC; RFA-CA-21-024), and Proteogenomic Translational Research Center (PTRC; RFA-CA-21-025) teams.

The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the renewal of three separate collaborations with Japan and the Republic of Korea (ROK), affirming the two countries’ commitment to international cancer research and care, expanding efforts in the emerging area of proteogenomics, and the goals of the reignited Cancer Moonshot.

Protein complexes are a fundamental component of physiological and pathological processes. Despite organisms having a limited number of genes and therefore a finite number of proteins at their disposal, the number of possible combinations amongst these proteins is essentially inexhaustible; myriad protein complexes are constantly being assembled and disassembled at different physiology and pathological status in order to perform the complex and diverse biological functions.